Insight Molecular Diagnostics Net Long-Term Debt 2014-2025 | IMDX
Insight Molecular Diagnostics net long-term debt from 2014 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
| Insight Molecular Diagnostics Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $-1 |
| 2021 | $-2 |
| 2020 | $1 |
| 2019 | $-2 |
| 2018 | $-1 |
| 2017 | $2 |
| 2016 | $0 |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.083B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.456B | 60.38 |
| Hims & Hers Health (HIMS) | United States | $12.904B | 134.07 |
| Doximity (DOCS) | United States | $11.414B | 52.84 |
| Tempus AI (TEM) | United States | $11.164B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.284B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.801B | 59.38 |
| Hinge Health (HNGE) | United States | $3.571B | 0.00 |
| Privia Health (PRVA) | United States | $2.402B | 164.21 |
| 10x Genomics (TXG) | United States | $1.737B | 0.00 |
| Schrodinger (SDGR) | United States | $1.631B | 0.00 |
| Phreesia (PHR) | United States | $1.585B | 0.00 |
| Azenta (AZTA) | United States | $1.576B | 73.26 |
| Enovis (ENOV) | United States | $1.573B | 8.77 |
| Clover Health Investments (CLOV) | United States | $1.545B | 0.00 |
| Omnicell (OMCL) | United States | $1.324B | 23.36 |
| Evolent Health (EVH) | United States | $1.166B | 99.30 |
| Claritev (CTEV) | United States | $0.652B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.559B | 0.00 |
| Standard BioTools (LAB) | United States | $0.532B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.487B | 0.00 |
| Talkspace (TALK) | United States | $0.421B | 125.75 |
| TruBridge (TBRG) | United States | $0.353B | 783.33 |
| Outset Medical (OM) | United States | $0.328B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.270B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.258B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.240B | 0.00 |
| CapsoVision (CV) | United States | $0.185B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.161B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.160B | 0.00 |
| American Well (AMWL) | United States | $0.140B | 0.00 |
| Pulmonx (LUNG) | United States | $0.134B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.118B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.118B | 0.00 |
| CareCloud (CCLD) | United States | $0.104B | 3.95 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.099B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.052B | 0.00 |
| HeartBeam (BEAT) | United States | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.026B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |